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PRELIMINARY AND SHORT REPORTS
DARKENING OF GRAY HAIR DURING PAItA-AMINO-BENZOIC ACID THERAPY*
CuRIe J. D. ZARAFONuTIS, M.D.
Graying of hair has long been a phenomenon of general interest. Although there is evi-
dence that genetic, hormonal, and nutritional elements may all be involved in the process,
the exact mechanism of graying remains obscure. (1) It is not surprising, therefore, that
numerous substances have been proposed as "cures" for gray hair. After careful clinical
evaluation, however, none of these has survived as a form of therapy for this condition.
One compound which experienced this cycle during the past decade is paraaininobenzoic
acid (PABA). In 1941, Sieve administered 200 mg. PABA daily to 30 patients who had defi-
nite achromotrichia. (2) He reported that after about 2 months of treatment all cases had
marked darkening of the hair. Brandaleone, et al. (3) studied the effects of the daily ad-
ministration of 200 mg. PABA, 100 mg. calcium pantothenate, and 50 gm. brewer's yeast
to gray-haired subjects. Only 2 of 33 individuals exhibited a significant change in color
during an 8 months period. Furthermore, it was not possible to attribute the result in these
2 subjects to PABA alone. Thus, the relationship, if any, of PABA to hair color has re-
mained questionable.
During the past 4 years an extensive investigation of the effects of PABA in a variety
of clinical conditions has been conducted in this laboratory. Altogether, about 250 patients
have received doses of from 6 to 48 grams daily of this compound.1 Approximately 150 of
the patients have been treated for intervals ranging from 4 weeks to 27 months. Early in
the study, a striking example of darkening of gray hair during PABA therapy was observed.
This led to careful observation for similar change in all gray-haired patients treated with
PABA.
The purpose of this report is to record the apparent effects of PABA on the hair of cer-
tain patients incident to its use for their respective primary diseases.
In order to eliminate slight or debatable changes, only those subjects who had markedly
gray or graying hair will be considered herein.2 Of the 150 patients who were treated for 4
weeks or longer, 20 belonged in this category at the beginning of treatment. In this group
were 7 men and 13 women whose ages ranged from 43 to 86 years. Five of the 20 underwent
definite change in hair color during PABA therapy. The relevant information concerning
these individuals is summarized briefly below.
Case 1. C. C., a 63 year old white male, was placed on PABA therapy for lymphoblastoma
cutis (4) on Feb. 11, 1948. He received 2 gm. of the sodium salt (NaPABA) every 2 hours
initially. Because of edema; however, the medication was changed to the potassium prep-
aration (KPAB). On Feb. 28, the dosage was reduced to 18 gm. daily, and later to 12—15
gm. where it has since been maintained.
At the time of admission, his hair was gray and sparse. After 2* months of treatment with
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I PABA is best administered as potassium or sodium-para-aminobenzoate. Generous
quantities of PABA were made available for administration to these patients by the B. L.
Lemke Co., Lodi, N.J.: Merck & Co., Rahway, N. J.: and Wyeth, Inc., Philadelphia, Pa.
It should be noted that alteration in hair color was observed in a few non-gray-haired
individuals. Changes from light brown to darker brown, and from light auburn to deeper
auburn shades have been seen.
399
400 ThE JOURNAL OF INVESTIGATIVE DERMATOLOGY
PABA, a general regrowth of hair was noted. Furthermore, the roots of the scalp hair were
all dark while the tips were gray. Subsequently, all of his hair became medium brown in
color. Upon inquiry, it was learned that his hair had been completely gray for at least 15
years preceding the PABA therapy.
Case 2. A. K., a 50 year old white housewife, was started on PABA for the treatment of
dermatomyositis (5) on September 18, 1947. NaPAB and later KPAB constituted the only
treatment administered over the next 26 months. The dosage was 24 gin. daily for 2 weeks,
then 12—14 gm. daily for 6 months. Thereafter, the patient took 6—8 gm. KPAB a day until
Dec. 2, 1949. This patient had undergone marked loss of hair which continued during the
first months of treatment. By April 12, 1948, however, the hair ceased falling out and some
regrowth was noticeable. By July 26, the scalp hair was much denser, and, furthermore,
it was dark brown for about 3 inches along the proximal ends of the hair shafts. The distal
ends were either light brown or gray. With continued growth and cutting during succeed-
ing months, her hair gradually became uniformly brown.
Case 3. R. F. B., a 68 year old white male, was begun on KPAB therapy for dermatitis
herpetiformis (6) on Jan. 25, 1949. He received 18—21 gm. a day. Before treatment, his scalp
hair was thin and almost completely gray. Within 2 months, definite regrowth and darken-
ing was noted. These changes were more striking after 5 months of therapy.
Case 4. L. S., a 57 year old white female, was given KPAB for the treatment of a general-
ized scaly erythroderma believed to be lymphoblastoma cutis. She received 14 gm. daily,
beginning on Sept. 12, 1949. Prior to the KPAB therapy, the scalp hair was white and very
thin. By Nov. 22, however, the scalp hair was growing in more densely, and the roots were
dark while the tips were white. The difference was even more remarkable 3 weeks later.
Case 5. V. E. S., a 42 year old white housewife, was begun on 12 gm. daily of KPAB for
the treatment of scieroderma on July 11, 1949. This patient had considerable gray hair at
the beginning of treatment. By January, 1950, however, definite darkening had resulted.
DISCUsSION
That darkening of gray hair may result from prolonged administration of para-amino-
benzoic acid is evident from the preceding case reports. These subjects had received from
6 to 24 gin. of PABA daily for treatment of their respective primary disorders. The effect
on hair color was first noted 6 weeks alter PABA therapy was begun in case 4, but a longer
interval was usually required to bring about the change. The effect was not uniform, how-
ever, since other patients, who received PABA for comparable periods, failed to exhibit
significant change in hair color. There appeared to be no correlation between the darken-
ing effect and the duration of grayness prior to treatment with PABA. The color altera-
tion was observed to occur during the administration of PABA alone. Supplemental vita-
min therapy appeared not to influence the effect on hair color in these subjects.
It should be noted that these patients were given large quantities of PABA in order to
control their disease processes. The amounts used, therefore, were far greater than those
employed by others (2, 3) who were deliberately seeking to alter gray hair. The mechanism
by which PABA may cause pigmentation of gray hair in certain individuals remains ob-
scure. Discussion at this time would, therefore, be non-contributory. It is hoped, however,
that further study of the metabolic activities of PABA will aid in clarifying the pigmenta-
tion processes. In this connection it appears worthy of note that in scleroderma and der-
matitis herpetiformis, the associated cutaneous hyperpigmentation usually fades to a
lighter, more natural coloration during PABA therapy (5, 6).
SUMMART
Darkening of gray hair was observed in 5 of 20 individuals who received large amounts
of para-aminobenzoic acid for treatment of certain clinical disorders. It is not advocated,
however, that PABA be administered solely for the purpose of trying to darken gray hair;
rather, it is hoped that the observations reported herein may prove to be of value in con-
nection with studies of pigment metabolism.
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